Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topiramate in Obese Patients With Mild to Moderate Hypertension
NCT00236665Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Mar 2001
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of topiramate in obesity and hypertension (HTN) (3 arms), sponsored by Johnson & Johnson. Primary endpoints: Percent change in body weight from baseline at 60 weeks and Percent change in sitting diastolic blood pressure from baseline at 60 weeks. Started Mar 2001; status: completed.
02
Drugs
topiramate
03
Conditions
obesityhypertension (HTN)
Beyond the preview
Go deeper on NCT00236665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00236665.